In the open-label, randomized, phase 3 INHALE-1 clinical trial (NCT04974528), an insulin human inhalation powder (Afrezza;…
Continue Reading
In the open-label, randomized, phase 3 INHALE-1 clinical trial (NCT04974528), an insulin human inhalation powder (Afrezza;…
Continue Reading